A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT ID: NCT06999187
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
96 participants
INTERVENTIONAL
2025-06-03
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
NCT00022217
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
NCT00003206
Docetaxel in Head and Neck Cancer
NCT00261703
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00095628
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT00116909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DL1 of DR-0202
Participants in this arm will receive DL1 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL2 of DR-0202
Participants in this arm will receive DL2 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL3 of DR-0202
Participants in this arm will receive DL3 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL4 of DR-0202
Participants in this arm will receive DL4 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL5 of DR-0202
Participants in this arm will receive DL5 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL6 of DR-0202
Participants in this arm will receive DL6 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL7 of DR-0202
Participants in this arm will receive DL7 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
DL8 of DR-0202
Participants in this arm will receive DL8 milligrams of DR-0202 every 2 weeks until progression or withdrawal
DR-0202
DR-0202 is a bispecific antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DR-0202
DR-0202 is a bispecific antibody
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available
* Radiographically measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Life expectancy, in the opinion of the Investigator, of ≥ 3 months
* Adequate marrow reserve, renal function, and hepatic function
* Taper of ≥ 2 weeks from high-dose systemic corticosteroids (however, low dose corticosteroids ≤ 25 mg prednisone or equivalent daily are permitted in consultation with the Medical Monitor)
* Willing to provide archival tumor tissue samples or agree to a baseline biopsy if not available
* Willing to undergo an on-treatment biopsy if clinically feasible and not contraindicated at the time of procedure
Exclusion Criteria
* Have not had an appropriate washout period from systemic therapy, including investigational agents, prior to C1D1:
1. Systemic chemotherapy and anticancer therapies within 4 weeks or 5 half-lives of the drug, whichever is shorter.
2. Antibody-based anticancer therapy: ≥ 4 weeks. Note: Treatment with systemic corticosteroids ≤ 25 mg/day (prednisone or equivalent) and inhaled or topical steroids are allowed. For participants with CRPC, LHRH agents are allowed.
* Radiation therapy within 21 days prior to C1D1. Palliative radiation therapy may be allowed following discussion with Medical Monitor
* Brain metastases either untreated and symptomatic or requiring therapy with steroids or anticonvulsants to control associated symptoms. Brain metastases that have been treated and are no longer symptomatic are allowed if use of high-dose systemic corticosteroids (\> 25 mg/day of prednisone or equivalent) is stopped ≥ 12 weeks prior to C1D1.
* Active Grade ≥ 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.
* Another malignancy (except for adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 1 year)
* Evidence of significant, uncontrolled concomitant disease that could affect compliance with study.
* Current or past history of CNS disease, such as stroke, epilepsy, central nervous system vasculitis or neurodegenerative disease (participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 6 months and have no residual neurologic deficits may be eligible).
* QT interval for heart rate using Fridericia's formula (QTcF) \> 480 msec or history of additional risk factors for Torsades de Pointes
* Uncontrolled or significant cardiovascular disease
* History or presence of an abnormal ECG that is clinically significant in the Investigator's opinion or myocardial infarction within 6 months prior to C1D1.
* Prior solid organ transplantation.
* Known infection with HIV, HBV, or HCV. The following participants may be enrolled in this study (the Sponsor reserves the right to restrict enrollment of these participants):
1. Participants who are HIV-positive with undetectable HIV RNA and at least 3 months on antiretroviral therapy.
2. Participants with a positive serologic test for HBV (i.e., positive HBcAb and negative HBsAg) and have a negative PCR test.
3. Participants who are HCV-positive who have completed at least 1 month of highly effective antiviral therapy and have a negative PCR test.
* Active infection requiring systemic treatment, defined as requiring IV antimicrobial, antifungal, or antiviral agents within 2 weeks prior to C1D1. Prophylactic antimicrobial treatment is allowed. Infections eligible per Exclusion Criterion 16 may be enrolled.
* Active clinical interstitial pneumonitis (e.g., shortness of breath, requirement of supplemental oxygen, dry cough) or as confirmed by means of diagnostic imaging within 6 months prior to C1D1.
* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dren Bio
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wan Jen Hong, MD
Role: STUDY_DIRECTOR
Dren Bio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dren Investigational Site
Denver, Colorado, United States
Dren Investigational Site
Orlando, Florida, United States
Dren Investigational Site
Sarasota, Florida, United States
Dren Investigational Site
Huntersville, North Carolina, United States
Dren Investigational Site
Oklahoma City, Oklahoma, United States
Dren Investigational Site
Greenville, South Carolina, United States
Dren Investigational Site
Austin, Texas, United States
Dren Investigational Site
Dallas, Texas, United States
Dren Investigational Site
San Antonio, Texas, United States
Dren Investigational Site
Fairfax, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DR-0202-ONC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.